With a well-established short-term evidence base, the low-FODMAP diet has become one of the most widely recommended dietary interventions for irritable bowel syndrome (IBS).
But dietary trials for IBS have typically measured outcomes during or immediately after the active intervention period.
What happens in the months that follow has received far less attention.
A 12-month randomised controlled trial published in Gut Microbes now addresses that gap … and the findings have implications that extend well beyond IBS management.1
The study
The trial enrolled adults with IBS in multiple centres and randomly assigned them to one of two dietary approaches: a microbiome-guided personalised diet or a standard low-FODMAP diet.
Both groups followed their assigned diet for 6 weeks, after which no further dietary guidance was provided.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
